Free Trial

Bristol-Myers Squibb (BMY) Financials

Bristol-Myers Squibb logo
$46.85 0.00 (0.00%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$46.86 +0.01 (+0.02%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Bristol-Myers Squibb

Annual Income Statements for Bristol-Myers Squibb

This table shows Bristol-Myers Squibb's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
-8,948 8,025 6,327 6,994 -9,015 3,439 4,920 1,007 4,457 1,565
Consolidated Net Income / (Loss)
-8,933 8,040 6,345 7,014 -8,995 3,460 4,947 975 4,507 1,631
Net Income / (Loss) Continuing Operations
-8,933 8,040 6,345 7,014 -8,995 3,460 4,947 975 4,507 1,631
Total Pre-Tax Income
-8,379 8,440 7,713 8,098 -6,871 4,975 5,968 5,131 5,915 2,077
Total Operating Income
-7,486 7,282 8,289 7,378 -9,185 5,913 5,114 3,446 4,467 1,890
Total Gross Profit
20,959 33,400 35,207 35,286 30,745 18,067 16,094 14,762 14,458 12,651
Total Revenue
48,300 45,006 46,159 46,385 42,518 26,145 22,561 20,776 19,427 16,560
Operating Revenue
48,300 45,006 46,159 46,385 42,518 26,145 22,561 20,776 19,427 14,045
Total Cost of Revenue
27,341 11,606 10,952 11,099 11,773 8,078 6,467 6,014 4,969 3,909
Operating Cost of Revenue
27,341 11,606 10,952 11,099 11,773 8,078 6,467 6,014 4,969 3,909
Total Operating Expenses
28,445 26,118 26,918 27,908 39,930 12,154 10,980 11,316 9,991 10,761
Selling, General & Admin Expense
8,414 7,772 7,814 7,690 7,661 4,871 4,551 4,751 4,979 4,841
Research & Development Expense
11,159 9,299 9,509 10,195 10,048 6,148 6,332 6,468 5,012 5,920
Amortization Expense
8,872 9,047 9,595 10,023 9,688 1,135 97 97 - -
Total Other Income / (Expense), net
-893 1,158 -576 720 2,314 -938 854 1,685 1,448 187
Other Income / (Expense), net
-893 1,158 -576 720 2,314 -938 854 1,685 1,448 187
Income Tax Expense
554 400 1,368 1,084 2,124 1,515 1,021 4,156 1,408 446
Net Income / (Loss) Attributable to Noncontrolling Interest
15 15 18 20 20 21 27 -32 50 66
Basic Earnings per Share
($4.41) $3.88 $2.97 $3.15 ($3.99) $2.02 $3.01 $0.61 $2.67 $0.94
Weighted Average Basic Shares Outstanding
2.03B 2.02B 2.10B 2.18B 2.24B 2.26B 1.63B 1.65B 1.67B 1.67B
Diluted Earnings per Share
($4.41) $3.86 $2.95 $3.12 ($3.99) $2.01 $3.01 $0.61 $2.65 $0.93
Weighted Average Diluted Shares Outstanding
2.03B 2.02B 2.10B 2.18B 2.24B 2.26B 1.63B 1.65B 1.67B 1.67B
Weighted Average Basic & Diluted Shares Outstanding
2.03B 2.02B 2.10B 2.18B 2.24B 2.26B 1.63B 1.65B 1.67B 1.67B
Cash Dividends to Common per Share
$2.42 $2.31 $2.19 $2.01 $1.84 $1.68 $1.61 $1.57 $1.53 $1.49

Quarterly Income Statements for Bristol-Myers Squibb

This table shows Bristol-Myers Squibb's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
2,456 72 1,211 1,680 -11,911 1,762 1,928 2,073 2,262 2,022 1,606
Consolidated Net Income / (Loss)
2,462 76 1,215 1,684 -11,908 1,762 1,934 2,077 2,267 2,025 1,608
Net Income / (Loss) Continuing Operations
2,462 76 1,215 1,684 -11,908 1,762 1,934 2,077 2,267 2,025 1,608
Total Pre-Tax Income
2,971 175 1,676 1,286 -11,516 1,674 2,137 1,859 2,770 1,859 2,209
Total Operating Income
3,309 480 1,910 1,559 -11,435 1,303 1,879 1,743 2,357 1,642 2,069
Total Gross Profit
7,980 7,500 8,673 8,802 -4,016 8,132 8,380 8,192 8,696 8,761 8,835
Total Revenue
11,201 12,342 11,892 12,201 11,865 11,477 10,966 11,226 11,337 11,406 11,218
Operating Revenue
11,201 12,342 11,892 12,201 11,865 11,477 10,966 11,226 11,337 11,406 11,218
Total Cost of Revenue
3,221 4,842 3,219 3,399 15,881 3,345 2,586 3,034 2,641 2,645 2,383
Operating Cost of Revenue
3,221 4,842 3,219 3,399 15,881 3,345 2,586 3,034 2,641 2,645 2,383
Total Operating Expenses
4,671 7,020 6,763 7,243 7,419 6,829 6,501 6,449 6,339 7,119 6,766
Selling, General & Admin Expense
1,584 2,136 1,983 1,928 2,367 2,073 2,003 1,934 1,762 2,266 1,930
Research & Development Expense
2,257 3,191 2,374 2,899 2,695 2,478 2,242 2,258 2,321 2,510 2,418
Amortization Expense
830 1,693 2,406 2,416 2,357 2,278 2,256 2,257 2,256 2,343 2,418
Total Other Income / (Expense), net
-339 -305 -234 -273 -81 371 258 116 413 217 140
Other Income / (Expense), net
-339 -305 -234 -273 -81 371 258 116 413 217 140
Income Tax Expense
509 99 461 -398 392 -88 203 -218 503 -166 601
Net Income / (Loss) Attributable to Noncontrolling Interest
6.00 4.00 4.00 4.00 3.00 - 6.00 4.00 5.00 3.00 2.00
Basic Earnings per Share
$1.21 $0.05 $0.60 $0.83 ($5.89) $0.87 $0.94 $0.99 $1.08 $0.95 $0.75
Weighted Average Basic Shares Outstanding
2.04B 2.03B 2.03B 2.03B 2.03B 2.02B 2.03B 2.09B 2.10B 2.10B 2.13B
Diluted Earnings per Share
$1.20 $0.05 $0.60 $0.83 ($5.89) $0.87 $0.93 $0.99 $1.07 $0.95 $0.75
Weighted Average Diluted Shares Outstanding
2.04B 2.03B 2.03B 2.03B 2.03B 2.02B 2.03B 2.09B 2.10B 2.10B 2.13B
Weighted Average Basic & Diluted Shares Outstanding
2.04B 2.03B 2.03B 2.03B 2.03B 2.02B 2.03B 2.09B 2.10B 2.10B 2.13B
Cash Dividends to Common per Share
$0.62 - $0.60 $0.60 $0.60 - $0.57 $0.57 $0.57 - $0.54

Annual Cash Flow Statements for Bristol-Myers Squibb

This table details how cash moves in and out of Bristol-Myers Squibb's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
-1,172 2,194 -4,991 -657 2,153 5,909 1,531 1,132 1,852 -3,186
Net Cash From Operating Activities
15,190 13,860 13,066 16,207 14,052 8,210 7,066 5,275 3,058 2,105
Net Cash From Continuing Operating Activities
15,190 13,860 13,066 16,207 14,052 8,210 7,066 5,275 3,058 2,105
Net Income / (Loss) Continuing Operations
-8,933 8,040 6,345 7,014 -8,995 3,460 4,947 975 4,507 1,631
Consolidated Net Income / (Loss)
-8,933 8,040 6,345 7,014 -8,995 3,460 4,947 975 4,507 1,631
Depreciation Expense
9,600 9,760 10,276 10,686 10,380 1,746 637 789 382 376
Non-Cash Adjustments To Reconcile Net Income
15,802 1,262 1,412 1,703 12,454 -1,453 1,034 677 -644 935
Changes in Operating Assets and Liabilities, net
-1,279 -5,202 -4,967 -3,196 213 2,769 262 2,598 -1,356 -1,082
Net Cash From Investing Activities
-21,352 -2,295 -1,062 -538 -10,859 -9,913 -2,000 -66 1,480 -1,572
Net Cash From Continuing Investing Activities
-21,352 -2,295 -1,062 -538 -10,859 -9,913 -2,000 -66 1,480 -1,572
Purchase of Property, Plant & Equipment
-1,248 -1,209 -1,118 -973 -753 -836 -951 -1,055 -1,215 -820
Acquisitions
-21,821 -1,169 -4,286 -1,610 -13,084 -24,777 -2,372 -726 -359 -1,111
Purchase of Investments
-769 -1,774 -3,592 -5,478 -4,172 -3,961 -2,305 -5,419 -3,089 -3,143
Divestitures
1,099 909 1,305 748 870 15,852 1,249 736 1,334 708
Sale and/or Maturity of Investments
1,387 948 6,629 6,775 6,280 3,809 2,379 6,398 4,809 2,794
Net Cash From Financing Activities
5,127 -9,416 -16,962 -16,224 -1,151 7,621 -3,535 -4,077 -2,653 -3,624
Net Cash From Continuing Financing Activities
5,127 -9,416 -16,962 -16,224 -1,151 7,621 -3,535 -4,077 -2,653 -3,624
Repayment of Debt
-5,774 -3,999 -11,237 -5,541 -2,475 -9,178 -602 -1,246 0.00 -2,406
Repurchase of Common Equity
0.00 -5,155 -8,001 -6,287 -1,546 -7,300 -320 -2,469 -231 0.00
Payment of Dividends
-4,863 -4,744 -4,634 -4,396 -4,075 -2,679 -2,613 -2,577 -2,547 -2,477
Issuance of Debt
15,870 4,455 5,926 0.00 6,945 26,778 0.00 2,215 125 1,259
Other Financing Activities, net
-106 27 984 - - - - - - -
Effect of Exchange Rate Changes
-137 45 -33 -102 111 -9.00 - - -33 -95

Quarterly Cash Flow Statements for Bristol-Myers Squibb

This table details how cash moves in and out of Bristol-Myers Squibb's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
528 2,454 1,597 -3,038 -2,185 3,951 -857 -623 -277 1,368 -3,003
Net Cash From Operating Activities
1,954 4,439 5,591 2,326 2,834 4,252 4,751 1,887 2,970 3,306 3,687
Net Cash From Continuing Operating Activities
1,954 4,439 5,591 2,326 2,834 4,252 4,751 1,887 2,970 3,306 3,687
Net Income / (Loss) Continuing Operations
2,462 76 1,215 1,684 -11,908 1,762 1,934 2,077 2,267 2,025 1,608
Consolidated Net Income / (Loss)
2,462 76 1,215 1,684 -11,908 1,762 1,934 2,077 2,267 2,025 1,608
Depreciation Expense
1,012 1,880 2,592 2,596 2,532 2,464 2,435 2,432 2,429 2,521 2,588
Non-Cash Adjustments To Reconcile Net Income
128 1,998 333 748 12,723 498 418 164 182 -158 -28
Changes in Operating Assets and Liabilities, net
-1,648 485 1,451 -2,702 -513 -472 -36 -2,786 -1,908 -1,082 -481
Net Cash From Investing Activities
-499 -196 -219 -1,319 -19,618 -1,346 -410 -329 -210 1,213 -2,081
Net Cash From Continuing Investing Activities
-499 -196 -219 -1,319 -19,618 -1,346 -410 -329 -210 1,213 -2,081
Purchase of Property, Plant & Equipment
-260 -378 -324 -262 -284 -330 -342 -259 -278 -346 -247
Acquisitions
-78 -47 -348 -1,373 -20,053 -581 -326 -184 -78 -116 -3,261
Purchase of Investments
-636 -371 -40 -84 -274 -717 -502 -355 -200 -26 -274
Divestitures
243 333 255 270 241 241 247 194 227 490 221
Sale and/or Maturity of Investments
232 267 238 130 752 41 513 275 119 1,211 1,480
Net Cash From Financing Activities
-993 -1,642 -3,852 -4,023 14,644 967 -5,160 -2,173 -3,050 -3,246 -4,543
Net Cash From Continuing Financing Activities
-993 -1,642 -3,852 -4,023 14,644 967 -5,160 -2,173 -3,050 -3,246 -4,543
Repayment of Debt
368 -405 -2,652 -5,787 3,070 -2,353 -10 -124 -1,512 136 -2,857
Payment of Dividends
-1,258 -1,218 -1,216 -1,217 -1,212 -1,160 -1,191 -1,197 -1,196 -1,145 -1,154
Issuance of Debt
0.00 - - 2,987 12,883 4,455 - - 0.00 - -
Other Financing Activities, net
-103 -19 16 -6.00 -97 25 41 53 -92 179 53
Effect of Exchange Rate Changes
66 -147 77 -22 -45 78 -38 -8.00 13 95 -66

Annual Balance Sheets for Bristol-Myers Squibb

This table presents Bristol-Myers Squibb's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
92,603 95,159 96,820 109,314 118,481 129,944 34,986 33,551 33,707 31,748
Total Current Assets
29,780 31,770 27,273 33,262 30,192 29,354 17,716 14,854 13,704 10,415
Cash & Equivalents
10,346 11,464 9,123 13,979 14,546 12,346 6,911 5,421 4,237 2,385
Short-Term Investments
513 816 130 2,987 1,285 3,047 1,848 1,391 2,113 1,885
Accounts Receivable
10,747 10,921 9,886 9,369 8,501 7,685 5,747 6,300 5,543 4,299
Inventories, net
2,557 2,662 2,339 2,095 2,074 4,293 1,195 1,166 1,241 1,221
Other Current Assets
5,617 5,907 5,795 4,832 3,786 1,983 2,015 576 570 625
Plant, Property, & Equipment, net
7,136 6,646 6,255 6,049 5,886 6,252 5,027 5,001 4,980 4,412
Total Noncurrent Assets
55,687 56,743 63,292 70,003 82,403 94,338 12,243 13,696 15,023 16,921
Long-Term Investments
320 364 0.00 - 433 767 1,775 2,480 2,719 4,660
Goodwill
21,719 21,169 21,149 20,502 20,547 22,488 6,538 6,863 6,875 6,881
Intangible Assets
23,307 27,072 35,859 42,527 53,243 63,969 1,091 1,210 1,385 1,419
Noncurrent Deferred & Refundable Income Taxes
4,236 2,768 1,344 1,439 1,161 510 815 1,610 2,996 2,844
Other Noncurrent Operating Assets
6,105 5,370 4,940 5,535 7,019 6,604 2,024 1,533 1,048 1,117
Total Liabilities & Shareholders' Equity
92,603 95,159 96,820 109,314 118,481 129,944 34,986 33,551 33,707 31,748
Total Liabilities
76,215 65,674 65,702 73,308 80,599 78,246 20,859 21,704 17,360 17,324
Total Current Liabilities
23,774 22,262 21,890 21,868 19,080 18,304 10,654 9,563 8,841 8,017
Short-Term Debt
2,046 3,119 4,264 4,948 2,340 3,346 1,703 987 992 139
Accounts Payable
3,602 3,259 3,040 2,949 2,713 2,445 1,892 2,248 1,664 1,565
Other Current Liabilities
18,126 15,884 14,586 13,971 14,027 12,513 7,059 - - -
Total Noncurrent Liabilities
52,441 43,412 43,812 51,440 61,519 59,942 10,205 12,141 8,519 9,307
Long-Term Debt
47,603 36,653 35,056 39,605 48,336 43,387 5,646 6,975 5,716 6,550
Noncurrent Deferred & Payable Income Tax Liabilities
369 338 2,166 4,501 5,407 6,454 19 - - -
Other Noncurrent Operating Liabilities
4,469 6,421 6,590 7,334 7,776 10,101 4,540 1,164 1,283 1,429
Commitments & Contingencies
0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
16,388 29,485 31,118 36,006 37,882 51,698 14,127 11,847 16,347 14,424
Total Preferred & Common Equity
16,335 29,430 31,061 35,946 37,822 51,598 14,031 11,741 16,177 14,266
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
16,335 29,430 31,061 35,946 37,822 51,598 14,031 11,741 16,177 14,266
Common Stock
46,316 45,976 45,457 44,653 44,617 44,001 2,302 2,119 1,946 1,680
Retained Earnings
14,912 28,766 25,503 23,820 21,281 34,474 34,065 31,160 33,513 31,613
Treasury Stock
-43,655 -43,766 -38,618 -31,259 -26,237 -25,357 -19,574 -19,249 -16,779 -16,559
Accumulated Other Comprehensive Income / (Loss)
-1,238 -1,546 -1,281 -1,268 -1,839 -1,520 -2,762 -2,289 -2,503 -2,468
Other Equity Adjustments
0.00 0.00 - - - 0.00 - - - -
Noncontrolling Interest
53 55 57 60 60 100 96 106 170 158

Quarterly Balance Sheets for Bristol-Myers Squibb

This table presents Bristol-Myers Squibb's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
92,427 92,603 93,670 94,646 99,031 95,159 91,263 93,489 94,281 96,820 98,196
Total Current Assets
30,783 29,780 28,075 26,890 28,669 31,770 27,632 28,074 27,086 27,273 26,796
Cash & Equivalents
10,875 10,346 7,890 6,293 9,330 11,464 7,514 8,372 8,995 9,123 7,734
Short-Term Investments
907 513 204 360 340 816 171 358 274 130 1,293
Accounts Receivable
10,801 10,747 11,026 11,423 10,447 10,921 10,304 10,112 10,054 9,886 9,613
Inventories, net
2,666 2,557 3,332 3,077 2,985 2,662 2,436 2,364 2,605 2,339 2,074
Other Current Assets
5,534 5,617 5,623 5,737 5,567 5,907 7,207 6,868 5,158 5,795 6,082
Plant, Property, & Equipment, net
7,213 7,136 6,903 6,845 6,750 6,646 6,481 6,355 6,279 6,255 6,035
Total Noncurrent Assets
54,430 55,687 58,692 60,911 63,612 56,743 56,825 59,060 60,916 63,292 65,365
Long-Term Investments
344 320 324 357 367 364 - - - 0.00 -
Goodwill
21,737 21,719 21,751 21,732 21,738 21,169 21,147 21,163 21,162 21,149 21,112
Intangible Assets
22,486 23,307 26,964 29,428 32,760 27,072 28,950 31,303 33,569 35,859 38,179
Noncurrent Deferred & Refundable Income Taxes
3,997 4,236 3,609 3,323 2,723 2,768 1,514 1,572 1,317 1,344 1,329
Other Noncurrent Operating Assets
5,866 6,105 6,044 6,071 6,024 5,370 5,214 5,022 4,868 4,940 4,745
Total Liabilities & Shareholders' Equity
92,427 92,603 93,670 94,646 99,031 95,159 91,263 93,489 94,281 96,820 98,196
Total Liabilities
74,979 76,215 76,470 77,577 82,483 65,674 62,201 61,459 62,395 65,702 65,462
Total Current Liabilities
24,070 23,774 22,638 23,265 25,822 22,262 23,462 20,150 19,085 21,890 18,930
Short-Term Debt
3,554 2,046 1,078 3,531 6,190 3,119 5,467 3,020 2,752 4,264 2,132
Accounts Payable
4,002 3,602 3,469 3,751 3,539 3,259 2,813 3,069 3,194 3,040 2,595
Other Current Liabilities
16,514 18,126 18,091 15,983 16,093 15,884 15,182 14,061 13,139 14,586 14,203
Total Noncurrent Liabilities
50,910 52,441 53,832 54,312 56,661 43,412 38,739 41,309 43,310 43,812 46,532
Long-Term Debt
46,157 47,603 48,674 48,858 49,487 36,653 32,137 34,656 35,078 35,056 36,966
Noncurrent Deferred & Payable Income Tax Liabilities
276 369 430 461 442 338 399 751 1,568 2,166 2,881
Other Noncurrent Operating Liabilities
4,477 4,469 4,728 4,993 6,732 6,421 6,203 5,902 6,664 6,590 6,685
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
17,448 16,388 17,200 17,069 16,548 29,485 29,062 32,030 31,886 31,118 32,734
Total Preferred & Common Equity
17,389 16,335 17,142 17,015 16,490 29,430 28,998 31,973 31,824 31,061 32,671
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
17,388 16,335 17,142 17,015 16,490 29,430 28,998 31,973 31,824 31,061 32,671
Common Stock
46,303 46,316 46,188 46,058 45,947 45,976 45,141 45,591 45,432 45,457 45,248
Retained Earnings
16,106 14,912 16,097 16,103 15,640 28,766 28,218 27,449 26,568 25,503 24,675
Treasury Stock
-43,597 -43,655 -43,675 -43,690 -43,697 -43,766 -43,075 -39,680 -38,808 -38,618 -36,411
Accumulated Other Comprehensive Income / (Loss)
-1,424 -1,238 -1,468 -1,456 -1,400 -1,546 -1,286 -1,387 -1,368 -1,281 -841
Noncontrolling Interest
59 53 58 54 58 55 64 57 62 57 63

Annual Metrics And Ratios for Bristol-Myers Squibb

This table displays calculated financial ratios and metrics derived from Bristol-Myers Squibb's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
7.32% -2.50% -0.49% 9.10% 62.62% 15.89% 8.59% 6.94% 17.31% 4.29%
EBITDA Growth
-93.29% 1.17% -4.23% 435.31% -58.27% 23.83% 10.32% -4.79% 139.66% -29.35%
EBIT Growth
-199.28% 9.43% -4.75% 217.86% -238.11% -16.64% 16.31% -13.25% 184.79% -12.77%
NOPAT Growth
-175.54% 1.73% 6.70% 199.39% -256.35% -2.99% 547.38% -80.76% 129.33% -32.78%
Net Income Growth
-211.11% 26.71% -9.54% 177.98% -359.97% -30.06% 407.38% -78.37% 176.33% -19.62%
EPS Growth
-214.25% 30.85% -5.45% 178.20% -298.51% -33.22% 393.44% -76.98% 184.95% -22.50%
Operating Cash Flow Growth
9.60% 6.08% -19.38% 15.34% 71.16% 16.19% 33.95% 72.50% 45.27% -33.13%
Free Cash Flow Firm Growth
-130.28% 24.73% -38.86% 325.41% 105.28% -1,862.32% -7.51% 157.63% 74.34% -77.27%
Invested Capital Growth
-3.10% -7.47% -3.79% -12.04% -12.13% 651.88% 4.04% -24.80% 14.80% 4.87%
Revenue Q/Q Growth
1.82% 0.16% -1.24% 2.02% 7.93% 8.16% 2.38% 1.00% 5.18% 0.18%
EBITDA Q/Q Growth
-63.04% -1.31% -0.28% 184.95% -71.74% -6.72% 12.14% -4.23% 30.78% -28.49%
EBIT Q/Q Growth
-21.79% -2.14% 0.09% 292.58% -299.10% -24.72% 15.64% -7.03% 33.85% -14.42%
NOPAT Q/Q Growth
-12.35% -5.45% -11.63% 227.79% -21,598.68% -30.79% 269.00% -77.20% 23.88% -28.02%
Net Income Q/Q Growth
-23.26% -3.17% -5.19% 230.25% -32,025.00% -39.06% 238.84% -76.80% 31.75% -11.65%
EPS Q/Q Growth
-22.84% -2.03% -3.91% 231.09% -1,275.86% -41.74% 234.44% -75.98% 32.50% -12.26%
Operating Cash Flow Q/Q Growth
1.25% 7.33% -5.44% 4.53% 9.12% -14.34% 52.68% -5.82% 22.37% 17.40%
Free Cash Flow Firm Q/Q Growth
23.27% 0.20% -17.82% 582.50% 105.52% -854.76% 44.05% 29.89% -14.79% 6.51%
Invested Capital Q/Q Growth
-6.28% -3.48% -2.58% -4.11% -1.68% 789.80% -10.38% -23.28% -0.19% -7.30%
Profitability Metrics
- - - - - - - - - -
Gross Margin
43.39% 74.21% 76.27% 76.07% 72.31% 69.10% 71.34% 71.05% 74.42% 76.39%
EBITDA Margin
2.53% 40.44% 38.97% 40.50% 8.25% 32.16% 30.10% 29.63% 33.28% 16.29%
Operating Margin
-15.50% 16.18% 17.96% 15.91% -21.60% 22.62% 22.67% 16.59% 22.99% 11.41%
EBIT Margin
-17.35% 18.75% 16.71% 17.46% -16.16% 19.03% 26.45% 24.70% 30.45% 12.54%
Profit (Net Income) Margin
-18.49% 17.86% 13.75% 15.12% -21.16% 13.23% 21.93% 4.69% 23.20% 9.85%
Tax Burden Percent
106.61% 95.26% 82.26% 86.61% 130.91% 69.55% 82.89% 19.00% 76.20% 78.53%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 4.74% 17.74% 13.39% 0.00% 30.45% 17.11% 81.00% 23.80% 21.47%
Return on Invested Capital (ROIC)
-9.40% 11.78% 10.93% 9.41% -8.32% 8.82% 39.51% 5.34% 26.01% 12.47%
ROIC Less NNEP Spread (ROIC-NNEP)
-20.66% 15.64% 9.29% 11.42% -16.22% 4.06% 8.15% -12.00% -21.94% 7.23%
Return on Net Nonoperating Assets (RNNOA)
-29.54% 14.76% 7.98% 9.58% -11.76% 1.69% -1.42% 1.57% 3.28% -1.38%
Return on Equity (ROE)
-38.95% 26.53% 18.91% 18.99% -20.08% 10.51% 38.09% 6.92% 29.29% 11.09%
Cash Return on Invested Capital (CROIC)
-6.25% 19.54% 14.79% 22.21% 4.59% -144.22% 35.55% 33.66% 12.23% 7.72%
Operating Return on Assets (OROA)
-8.93% 8.79% 7.48% 7.11% -5.53% 6.03% 17.42% 15.26% 18.07% 6.34%
Return on Assets (ROA)
-9.52% 8.38% 6.16% 6.16% -7.24% 4.20% 14.44% 2.90% 13.77% 4.98%
Return on Common Equity (ROCE)
-38.86% 26.48% 18.87% 18.95% -20.05% 10.48% 37.80% 6.85% 28.98% 10.98%
Return on Equity Simple (ROE_SIMPLE)
-54.69% 27.32% 20.43% 19.51% -23.78% 6.71% 35.26% 8.30% 27.86% 11.43%
Net Operating Profit after Tax (NOPAT)
-5,240 6,937 6,819 6,390 -6,430 4,112 4,239 655 3,404 1,484
NOPAT Margin
-10.85% 15.41% 14.77% 13.78% -15.12% 15.73% 18.79% 3.15% 17.52% 8.96%
Net Nonoperating Expense Percent (NNEP)
11.26% -3.86% 1.64% -2.01% 7.90% 4.76% 31.36% 17.35% 47.95% 5.24%
Return On Investment Capital (ROIC_SIMPLE)
-7.94% 10.02% 9.68% - - - - - - -
Cost of Revenue to Revenue
56.61% 25.79% 23.73% 23.93% 27.69% 30.90% 28.66% 28.95% 25.58% 23.61%
SG&A Expenses to Revenue
17.42% 17.27% 16.93% 16.58% 18.02% 18.63% 20.17% 22.87% 25.63% 29.23%
R&D to Revenue
23.10% 20.66% 20.60% 21.98% 23.63% 23.52% 28.07% 31.13% 25.80% 35.75%
Operating Expenses to Revenue
58.89% 58.03% 58.32% 60.17% 93.91% 46.49% 48.67% 54.47% 51.43% 64.98%
Earnings before Interest and Taxes (EBIT)
-8,379 8,440 7,713 8,098 -6,871 4,975 5,968 5,131 5,915 2,077
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,221 18,200 17,989 18,784 3,509 8,409 6,791 6,156 6,466 2,698
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
6.95 3.34 4.48 3.56 3.35 1.76 5.09 7.00 4.82 6.30
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 11.15 22.41 9.84 15.07
Price to Revenue (P/Rev)
2.35 2.18 3.01 2.76 2.98 3.48 3.16 3.96 4.01 5.43
Price to Earnings (P/E)
0.00 12.25 21.98 18.32 0.00 26.47 14.51 81.62 17.48 57.45
Dividend Yield
4.29% 4.72% 3.30% 3.40% 3.28% 2.94% 3.66% 3.11% 3.26% 2.76%
Earnings Yield
0.00% 8.16% 4.55% 5.46% 0.00% 3.78% 6.89% 1.23% 5.72% 1.74%
Enterprise Value to Invested Capital (EV/IC)
2.77 2.22 2.77 2.45 2.23 1.48 6.24 7.70 5.41 7.21
Enterprise Value to Revenue (EV/Rev)
3.15 2.79 3.67 3.36 3.79 4.66 3.03 3.90 3.90 5.30
Enterprise Value to EBITDA (EV/EBITDA)
124.48 6.89 9.41 8.29 45.95 14.47 10.06 13.15 11.71 32.55
Enterprise Value to EBIT (EV/EBIT)
0.00 14.87 21.94 19.24 0.00 24.46 11.45 15.78 12.80 42.29
Enterprise Value to NOPAT (EV/NOPAT)
0.00 18.09 24.81 24.38 0.00 29.60 16.11 123.65 22.25 59.18
Enterprise Value to Operating Cash Flow (EV/OCF)
10.01 9.05 12.95 9.61 11.48 14.82 9.67 15.35 24.76 41.72
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 10.90 18.34 10.32 45.46 0.00 17.91 19.63 47.31 95.66
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
3.03 1.35 1.26 1.24 1.34 0.90 0.52 0.67 0.41 0.46
Long-Term Debt to Equity
2.90 1.24 1.13 1.10 1.28 0.84 0.40 0.59 0.35 0.45
Financial Leverage
1.43 0.94 0.86 0.84 0.73 0.42 -0.17 -0.13 -0.15 -0.19
Leverage Ratio
4.09 3.17 3.07 3.08 2.77 2.51 2.64 2.39 2.13 2.23
Compound Leverage Factor
4.09 3.17 3.07 3.08 2.77 2.51 2.64 2.39 2.13 2.23
Debt to Total Capital
75.18% 57.43% 55.82% 55.30% 57.22% 47.48% 34.22% 40.19% 29.10% 31.68%
Short-Term Debt to Total Capital
3.10% 4.50% 6.05% 6.14% 2.64% 3.40% 7.93% 4.98% 4.30% 0.66%
Long-Term Debt to Total Capital
72.09% 52.92% 49.77% 49.16% 54.58% 44.08% 26.29% 35.21% 24.79% 31.02%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.08% 0.08% 0.08% 0.07% 0.07% 0.10% 0.45% 0.54% 0.74% 0.75%
Common Equity to Total Capital
24.74% 42.49% 44.10% 44.62% 42.71% 52.42% 65.33% 59.27% 70.17% 67.57%
Debt to EBITDA
40.66 2.19 2.19 2.37 14.44 5.56 1.08 1.29 1.04 2.48
Net Debt to EBITDA
31.51 1.49 1.67 1.47 9.81 3.64 -0.47 -0.22 -0.37 -0.83
Long-Term Debt to EBITDA
38.99 2.01 1.95 2.11 13.77 5.16 0.83 1.13 0.88 2.43
Debt to NOPAT
-9.47 5.73 5.77 6.97 -7.88 11.36 1.73 12.16 1.97 4.51
Net Debt to NOPAT
-7.34 3.91 4.41 4.32 -5.35 7.43 -0.75 -2.03 -0.69 -1.51
Long-Term Debt to NOPAT
-9.08 5.28 5.14 6.20 -7.52 10.55 1.33 10.65 1.68 4.41
Altman Z-Score
1.42 2.21 2.45 2.15 1.48 1.50 4.87 4.89 5.41 5.34
Noncontrolling Interest Sharing Ratio
0.24% 0.18% 0.17% 0.16% 0.18% 0.30% 0.78% 0.98% 1.07% 0.98%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.25 1.43 1.25 1.52 1.58 1.60 1.66 1.55 1.55 1.30
Quick Ratio
0.91 1.04 0.87 1.20 1.28 1.26 1.36 1.37 1.35 1.07
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3,485 11,509 9,227 15,091 3,548 -67,217 3,814 4,124 1,601 918
Operating Cash Flow to CapEx
1,217.15% 1,146.40% 1,168.69% 1,665.67% 1,866.14% 982.06% 743.01% 500.00% 251.69% 256.71%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.51 0.47 0.45 0.41 0.34 0.32 0.66 0.62 0.59 0.51
Accounts Receivable Turnover
4.46 4.33 4.79 5.19 5.25 3.89 3.75 3.51 3.95 4.31
Inventory Turnover
10.48 4.64 4.94 5.32 3.70 2.94 5.48 5.00 4.04 2.81
Fixed Asset Turnover
7.01 6.98 7.50 7.77 7.01 4.64 4.50 4.16 4.14 3.75
Accounts Payable Turnover
7.97 3.69 3.66 3.92 4.56 3.73 3.12 3.07 3.08 1.93
Days Sales Outstanding (DSO)
81.87 84.37 76.13 70.31 69.48 93.76 97.45 104.03 92.46 84.74
Days Inventory Outstanding (DIO)
34.84 78.64 73.89 68.55 98.70 123.99 66.63 73.04 90.42 129.84
Days Payable Outstanding (DPO)
45.80 99.05 99.80 93.10 79.96 97.98 116.83 118.71 118.59 189.18
Cash Conversion Cycle (CCC)
70.91 63.96 50.22 45.76 88.22 119.76 47.25 58.36 64.29 25.40
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
54,858 56,613 61,185 63,593 72,294 82,271 10,942 10,517 13,986 12,183
Invested Capital Turnover
0.87 0.76 0.74 0.68 0.55 0.56 2.10 1.70 1.48 1.39
Increase / (Decrease) in Invested Capital
-1,755 -4,572 -2,408 -8,701 -9,977 71,329 425 -3,469 1,803 566
Enterprise Value (EV)
151,984 125,477 169,192 155,767 161,256 121,711 68,308 80,969 75,730 87,831
Market Capitalization
113,461 98,294 139,068 128,120 126,784 91,038 71,397 82,193 77,921 89,914
Book Value per Share
$8.05 $14.46 $14.61 $16.19 $16.74 $31.67 $8.60 $7.17 $9.68 $8.55
Tangible Book Value per Share
($14.15) ($9.24) ($12.20) ($12.20) ($15.92) ($21.40) $3.92 $2.24 $4.74 $3.58
Total Capital
66,037 69,257 70,438 80,559 88,558 98,431 21,476 19,809 23,055 21,113
Total Debt
49,649 39,772 39,320 44,553 50,676 46,733 7,349 7,962 6,708 6,689
Total Long-Term Debt
47,603 36,653 35,056 39,605 48,336 43,387 5,646 6,975 5,716 6,550
Net Debt
38,470 27,128 30,067 27,587 34,412 30,573 -3,185 -1,330 -2,361 -2,241
Capital Expenditures (CapEx)
1,248 1,209 1,118 973 753 836 951 1,055 1,215 820
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2,807 347 394 -624 -2,379 -997 6.00 -534 -495 -1,733
Debt-free Net Working Capital (DFNWC)
8,052 12,627 9,647 16,342 13,452 14,396 8,765 6,278 5,855 2,537
Net Working Capital (NWC)
6,006 9,508 5,383 11,394 11,112 11,050 7,062 5,291 4,863 2,398
Net Nonoperating Expense (NNE)
3,693 -1,103 474 -624 2,566 652 -708 -320 -1,103 -147
Net Nonoperating Obligations (NNO)
38,470 27,128 30,067 27,587 34,412 30,573 -3,185 -1,330 -2,361 -2,241
Total Depreciation and Amortization (D&A)
9,600 9,760 10,276 10,686 10,380 3,434 823 1,025 551 621
Debt-free, Cash-free Net Working Capital to Revenue
-5.81% 0.77% 0.85% -1.35% -5.60% -3.81% 0.03% -2.57% -2.55% -10.47%
Debt-free Net Working Capital to Revenue
16.67% 28.06% 20.90% 35.23% 31.64% 55.06% 38.85% 30.22% 30.14% 15.32%
Net Working Capital to Revenue
12.43% 21.13% 11.66% 24.56% 26.13% 42.26% 31.30% 25.47% 25.03% 14.48%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($4.41) $3.88 $2.97 $3.15 ($3.99) $2.02 $3.01 $0.61 $2.67 $0.94
Adjusted Weighted Average Basic Shares Outstanding
2.03B 2.02B 2.10B 2.18B 2.24B 2.26B 1.63B 1.63B 1.67B 1.67B
Adjusted Diluted Earnings per Share
($4.41) $3.86 $2.95 $3.12 ($3.99) $2.01 $3.01 $0.61 $2.65 $0.93
Adjusted Weighted Average Diluted Shares Outstanding
2.03B 2.02B 2.10B 2.18B 2.24B 2.26B 1.63B 1.63B 1.67B 1.67B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $2.02 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.03B 2.02B 2.10B 2.18B 2.24B 2.26B 1.63B 1.63B 1.67B 1.67B
Normalized Net Operating Profit after Tax (NOPAT)
-5,240 6,937 6,819 6,390 -6,430 4,112 4,239 2,412 3,404 1,484
Normalized NOPAT Margin
-10.85% 15.41% 14.77% 13.78% -15.12% 15.73% 18.79% 11.61% 17.52% 8.96%
Pre Tax Income Margin
-17.35% 18.75% 16.71% 17.46% -16.16% 19.03% 26.45% 24.70% 30.45% 12.54%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
-54.44% 59.01% 73.03% 62.67% -45.30% 77.43% 52.82% 264.31% 56.51% 151.87%
Augmented Payout Ratio
-54.44% 123.12% 199.13% 152.31% -62.49% 288.41% 59.29% 517.54% 61.64% 151.87%

Quarterly Metrics And Ratios for Bristol-Myers Squibb

This table displays calculated financial ratios and metrics derived from Bristol-Myers Squibb's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-5.60% 7.54% 8.44% 8.69% 4.66% 0.62% -2.25% -5.56% -2.67% -4.83% -3.49%
EBITDA Growth
144.32% -50.34% -6.65% -9.53% -272.80% -5.53% -4.69% -5.51% 21.73% -1.15% -1.78%
EBIT Growth
125.79% -89.55% -21.57% -30.82% -515.74% -9.95% -3.26% -5.06% 64.20% 0.38% 2.41%
NOPAT Growth
134.26% -84.80% -18.58% 4.83% -514.96% -23.32% 12.91% 19.01% 8.58% -37.59% 19.75%
Net Income Growth
120.68% -95.69% -37.18% -18.92% -625.28% -12.99% 20.27% 45.35% 76.70% -14.63% 3.61%
EPS Growth
120.37% -94.25% -35.48% -16.16% -650.47% -8.42% 24.00% 50.00% 81.36% -11.22% 8.70%
Operating Cash Flow Growth
-31.05% 4.40% 17.68% 23.26% -4.58% 28.61% 28.86% -16.54% -22.09% -18.51% -29.98%
Free Cash Flow Firm Growth
201.58% -66.96% -74.24% -76.89% -411.26% 41.63% 16.57% -72.81% -71.18% -63.72% -40.75%
Invested Capital Growth
-11.51% -3.10% -0.21% 2.41% 2.88% -7.47% -6.61% -0.84% -1.95% -3.79% -5.30%
Revenue Q/Q Growth
-9.24% 3.78% -2.53% 2.83% 3.38% 4.66% -2.32% -0.98% -0.60% 1.68% -5.63%
EBITDA Q/Q Growth
93.77% -51.85% 9.94% 143.21% -317.11% -9.49% 6.55% -17.46% 18.70% -8.69% 5.64%
EBIT Q/Q Growth
1,597.14% -89.56% 30.33% 111.17% -787.93% -21.67% 14.95% -32.89% 49.00% -15.84% 12.82%
NOPAT Q/Q Growth
1,215.42% -84.95% -32.18% 125.50% -683.63% -19.35% -12.68% 0.95% 7.85% 18.76% -7.96%
Net Income Q/Q Growth
3,139.47% -93.74% -27.85% 114.14% -775.82% -8.89% -6.88% -8.38% 11.95% 25.93% 12.53%
EPS Q/Q Growth
2,300.00% -91.67% -27.71% 114.09% -777.01% -6.45% -6.06% -7.48% 12.63% 26.67% 13.64%
Operating Cash Flow Q/Q Growth
-55.98% -20.60% 140.37% -17.93% -33.35% -10.50% 151.78% -36.46% -10.16% -10.33% 63.07%
Free Cash Flow Firm Q/Q Growth
404.17% 30.32% 164.56% 105.84% -263.97% 1.61% 137.36% -21.29% -25.39% -16.37% -44.63%
Invested Capital Q/Q Growth
0.32% -6.28% -6.27% 0.42% 9.85% -3.48% -3.80% 0.88% -1.21% -2.58% 2.13%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
71.24% 60.77% 72.93% 72.14% -33.85% 70.85% 76.42% 72.97% 76.70% 76.81% 78.76%
EBITDA Margin
35.55% 16.65% 35.89% 31.82% -75.72% 36.05% 41.69% 38.22% 45.86% 38.40% 42.76%
Operating Margin
29.54% 3.89% 16.06% 12.78% -96.38% 11.35% 17.13% 15.53% 20.79% 14.40% 18.44%
EBIT Margin
26.52% 1.42% 14.09% 10.54% -97.06% 14.59% 19.49% 16.56% 24.43% 16.30% 19.69%
Profit (Net Income) Margin
21.98% 0.62% 10.22% 13.80% -100.36% 15.35% 17.64% 18.50% 20.00% 17.75% 14.33%
Tax Burden Percent
82.87% 43.43% 72.49% 130.95% 103.40% 105.26% 90.50% 111.73% 81.84% 108.93% 72.79%
Interest Burden Percent
100.03% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
17.13% 56.57% 27.51% -30.95% 0.00% -5.26% 9.50% -11.73% 18.16% -8.93% 27.21%
Return on Invested Capital (ROIC)
19.90% 1.46% 9.43% 12.61% -50.10% 9.13% 11.47% 12.80% 12.78% 11.60% 9.72%
ROIC Less NNEP Spread (ROIC-NNEP)
19.22% 1.06% 8.95% 11.65% -60.62% 10.50% 12.26% 13.25% 13.93% 12.42% 10.06%
Return on Net Nonoperating Assets (RNNOA)
47.06% 1.52% 13.72% 17.63% -92.87% 9.91% 11.83% 11.83% 12.84% 10.67% 8.50%
Return on Equity (ROE)
66.96% 2.98% 23.14% 30.24% -142.97% 19.04% 23.31% 24.63% 25.62% 22.27% 18.21%
Cash Return on Invested Capital (CROIC)
23.23% -6.25% -7.75% -9.98% -10.27% 19.54% 18.91% 12.54% 13.31% 14.79% 17.39%
Operating Return on Assets (OROA)
13.19% 0.73% 7.23% 5.21% -45.72% 6.84% 9.24% 7.72% 11.35% 7.30% 8.80%
Return on Assets (ROA)
10.94% 0.32% 5.24% 6.82% -47.28% 7.20% 8.37% 8.63% 9.29% 7.95% 6.41%
Return on Common Equity (ROCE)
66.73% 2.97% 23.08% 30.17% -142.61% 19.00% 23.26% 24.59% 25.57% 22.23% 18.18%
Return on Equity Simple (ROE_SIMPLE)
31.27% 0.00% -42.28% -38.37% -37.20% 0.00% 28.63% 24.95% 23.03% 0.00% 20.48%
Net Operating Profit after Tax (NOPAT)
2,742 208 1,385 2,041 -8,005 1,371 1,701 1,947 1,929 1,789 1,506
NOPAT Margin
24.48% 1.69% 11.64% 16.73% -67.46% 11.95% 15.51% 17.35% 17.02% 15.68% 13.43%
Net Nonoperating Expense Percent (NNEP)
0.67% 0.40% 0.48% 0.96% 10.52% -1.37% -0.78% -0.45% -1.15% -0.82% -0.34%
Return On Investment Capital (ROIC_SIMPLE)
4.08% 0.32% - - - 1.98% - - - 2.54% -
Cost of Revenue to Revenue
28.76% 39.23% 27.07% 27.86% 133.85% 29.15% 23.58% 27.03% 23.30% 23.19% 21.24%
SG&A Expenses to Revenue
14.14% 17.31% 16.68% 15.80% 19.95% 18.06% 18.27% 17.23% 15.54% 19.87% 17.20%
R&D to Revenue
20.15% 25.85% 19.96% 23.76% 22.71% 21.59% 20.45% 20.11% 20.47% 22.01% 21.55%
Operating Expenses to Revenue
41.70% 56.88% 56.87% 59.36% 62.53% 59.50% 59.28% 57.45% 55.91% 62.41% 60.31%
Earnings before Interest and Taxes (EBIT)
2,970 175 1,676 1,286 -11,516 1,674 2,137 1,859 2,770 1,859 2,209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,982 2,055 4,268 3,882 -8,984 4,138 4,572 4,291 5,199 4,380 4,797
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
7.04 6.95 6.05 4.87 6.61 3.34 3.94 3.97 4.35 4.48 4.40
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.57 2.35 2.19 1.78 2.40 2.18 2.54 2.81 3.02 3.01 3.08
Price to Earnings (P/E)
22.59 0.00 0.00 0.00 0.00 12.25 13.79 15.93 18.92 21.98 21.54
Dividend Yield
4.01% 4.29% 4.63% 5.72% 4.31% 4.72% 4.11% 3.68% 3.32% 3.30% 3.13%
Earnings Yield
4.43% 0.00% 0.00% 0.00% 0.00% 8.16% 7.25% 6.28% 5.28% 4.55% 4.64%
Enterprise Value to Invested Capital (EV/IC)
2.91 2.77 2.48 2.06 2.49 2.22 2.46 2.56 2.76 2.77 2.77
Enterprise Value to Revenue (EV/Rev)
3.36 3.15 3.06 2.76 3.40 2.79 3.21 3.45 3.64 3.67 3.72
Enterprise Value to EBITDA (EV/EBITDA)
11.28 124.48 43.93 35.58 38.53 6.89 7.82 8.35 8.83 9.41 9.64
Enterprise Value to EBIT (EV/EBIT)
26.21 0.00 0.00 0.00 0.00 14.87 16.72 17.92 18.98 21.94 22.57
Enterprise Value to NOPAT (EV/NOPAT)
24.78 0.00 0.00 0.00 0.00 18.09 19.66 21.76 24.11 24.81 22.54
Enterprise Value to Operating Cash Flow (EV/OCF)
11.19 10.01 9.67 9.06 11.28 9.05 11.17 13.16 13.66 12.95 12.59
Enterprise Value to Free Cash Flow (EV/FCFF)
11.76 0.00 0.00 0.00 0.00 10.90 12.56 20.29 20.55 18.34 15.49
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
2.85 3.03 2.89 3.07 3.36 1.35 1.29 1.18 1.19 1.26 1.19
Long-Term Debt to Equity
2.65 2.90 2.83 2.86 2.99 1.24 1.11 1.08 1.10 1.13 1.13
Financial Leverage
2.45 1.43 1.53 1.51 1.53 0.94 0.97 0.89 0.92 0.86 0.84
Leverage Ratio
5.63 4.09 4.00 3.83 3.99 3.17 3.07 3.00 3.11 3.07 2.99
Compound Leverage Factor
5.63 4.09 4.00 3.83 3.99 3.17 3.07 3.00 3.11 3.07 2.99
Debt to Total Capital
74.02% 75.18% 74.31% 75.43% 77.09% 57.43% 56.41% 54.05% 54.26% 55.82% 54.43%
Short-Term Debt to Total Capital
5.29% 3.10% 1.61% 5.08% 8.57% 4.50% 8.20% 4.33% 3.95% 6.05% 2.97%
Long-Term Debt to Total Capital
68.73% 72.09% 72.70% 70.34% 68.52% 52.92% 48.21% 49.72% 50.32% 49.77% 51.46%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.09% 0.08% 0.09% 0.08% 0.08% 0.08% 0.10% 0.08% 0.09% 0.08% 0.09%
Common Equity to Total Capital
25.89% 24.74% 25.60% 24.50% 22.83% 42.49% 43.50% 45.87% 45.65% 44.10% 45.48%
Debt to EBITDA
3.50 40.66 15.06 14.52 13.86 2.19 2.04 2.02 2.00 2.19 2.17
Net Debt to EBITDA
2.65 31.51 12.51 12.58 11.36 1.49 1.62 1.55 1.51 1.67 1.67
Long-Term Debt to EBITDA
3.25 38.99 14.73 13.54 12.32 2.01 1.74 1.86 1.85 1.95 2.05
Debt to NOPAT
7.69 -9.47 -10.67 -11.18 -12.22 5.73 5.13 5.26 5.46 5.77 5.07
Net Debt to NOPAT
5.82 -7.34 -8.86 -9.68 -10.02 3.91 4.08 4.04 4.12 4.41 3.90
Long-Term Debt to NOPAT
7.14 -9.08 -10.44 -10.43 -10.86 5.28 4.38 4.84 5.07 5.14 4.79
Altman Z-Score
1.93 1.72 1.69 1.46 1.13 1.97 2.16 2.30 2.41 2.25 2.32
Noncontrolling Interest Sharing Ratio
0.35% 0.24% 0.26% 0.23% 0.25% 0.18% 0.21% 0.18% 0.20% 0.17% 0.19%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.28 1.25 1.24 1.16 1.11 1.43 1.18 1.39 1.42 1.25 1.42
Quick Ratio
0.94 0.91 0.84 0.78 0.78 1.04 0.77 0.94 1.01 0.87 0.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
9,899 1,963 1,507 569 -9,746 5,943 5,850 2,464 3,131 4,197 5,018
Operating Cash Flow to CapEx
751.54% 1,174.34% 1,725.62% 887.79% 997.89% 1,288.48% 1,389.18% 728.57% 1,068.35% 955.49% 1,492.71%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.50 0.51 0.51 0.49 0.47 0.47 0.47 0.47 0.46 0.45 0.45
Accounts Receivable Turnover
4.48 4.46 4.45 4.32 4.44 4.33 4.51 4.72 4.94 4.79 4.96
Inventory Turnover
5.20 10.48 8.96 9.27 8.89 4.64 4.84 4.75 4.58 4.94 4.53
Fixed Asset Turnover
6.82 7.01 7.09 7.05 6.99 6.98 7.18 7.33 7.44 7.50 7.85
Accounts Payable Turnover
3.89 7.97 8.23 7.39 7.38 3.69 4.03 3.60 3.52 3.66 3.63
Days Sales Outstanding (DSO)
81.40 81.87 82.06 84.50 82.17 84.37 80.89 77.41 73.90 76.13 73.64
Days Inventory Outstanding (DIO)
70.25 34.84 40.73 39.39 41.06 78.64 75.47 76.83 79.65 73.89 80.56
Days Payable Outstanding (DPO)
93.74 45.80 44.36 49.37 49.46 99.05 90.50 101.47 103.83 99.80 100.58
Cash Conversion Cycle (CCC)
57.91 70.91 78.43 74.52 73.77 63.96 65.86 52.77 49.73 50.22 53.62
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
55,031 54,858 58,534 62,448 62,188 56,613 58,656 60,976 60,447 61,185 62,805
Invested Capital Turnover
0.81 0.87 0.81 0.75 0.74 0.76 0.74 0.74 0.75 0.74 0.72
Increase / (Decrease) in Invested Capital
-7,157 -1,755 -122 1,472 1,741 -4,572 -4,149 -517 -1,202 -2,408 -3,512
Enterprise Value (EV)
160,085 151,984 145,128 128,358 154,774 125,477 144,239 155,891 166,961 169,192 173,929
Market Capitalization
122,441 113,461 103,736 82,925 109,076 98,294 114,256 126,888 138,338 139,068 143,795
Book Value per Share
$8.57 $8.05 $8.46 $8.39 $8.13 $14.46 $13.88 $15.22 $15.16 $14.61 $15.30
Tangible Book Value per Share
($13.22) ($14.15) ($15.57) ($16.84) ($18.75) ($9.24) ($10.10) ($9.75) ($10.91) ($12.20) ($12.47)
Total Capital
67,159 66,037 66,952 69,458 72,225 69,257 66,666 69,706 69,716 70,438 71,832
Total Debt
49,711 49,649 49,752 52,389 55,677 39,772 37,604 37,676 37,830 39,320 39,098
Total Long-Term Debt
46,157 47,603 48,674 48,858 49,487 36,653 32,137 34,656 35,078 35,056 36,966
Net Debt
37,585 38,470 41,334 45,379 45,640 27,128 29,919 28,946 28,561 30,067 30,071
Capital Expenditures (CapEx)
260 378 324 262 284 330 342 259 278 346 247
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1,515 -2,807 -1,579 503 -633 347 1,952 2,214 1,484 394 971
Debt-free Net Working Capital (DFNWC)
10,267 8,052 6,515 7,156 9,037 12,627 9,637 10,944 10,753 9,647 9,998
Net Working Capital (NWC)
6,713 6,006 5,437 3,625 2,847 9,508 4,170 7,924 8,001 5,383 7,866
Net Nonoperating Expense (NNE)
280 132 170 357 3,904 -391 -233 -130 -338 -236 -102
Net Nonoperating Obligations (NNO)
37,583 38,470 41,334 45,379 45,640 27,128 29,594 28,946 28,561 30,067 30,071
Total Depreciation and Amortization (D&A)
1,012 1,880 2,592 2,596 2,532 2,464 2,435 2,432 2,429 2,521 2,588
Debt-free, Cash-free Net Working Capital to Revenue
-3.18% -5.81% -3.33% 1.08% -1.39% 0.77% 4.34% 4.90% 3.24% 0.85% 2.08%
Debt-free Net Working Capital to Revenue
21.55% 16.67% 13.73% 15.39% 19.85% 28.06% 21.45% 24.22% 23.45% 20.90% 21.39%
Net Working Capital to Revenue
14.09% 12.43% 11.46% 7.79% 6.25% 21.13% 9.28% 17.54% 17.45% 11.66% 16.83%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.21 $0.05 $0.60 $0.83 ($5.89) $0.87 $0.94 $0.99 $1.08 $0.95 $0.75
Adjusted Weighted Average Basic Shares Outstanding
2.04B 2.03B 2.03B 2.03B 2.03B 2.02B 2.03B 2.09B 2.10B 2.10B 2.13B
Adjusted Diluted Earnings per Share
$1.20 $0.05 $0.60 $0.83 ($5.89) $0.87 $0.93 $0.99 $1.07 $0.95 $0.75
Adjusted Weighted Average Diluted Shares Outstanding
2.04B 2.03B 2.03B 2.03B 2.03B 2.02B 2.03B 2.09B 2.10B 2.10B 2.13B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.04B 2.03B 2.03B 2.03B 2.03B 2.02B 2.03B 2.09B 2.10B 2.10B 2.13B
Normalized Net Operating Profit after Tax (NOPAT)
2,742 336 1,385 1,091 -8,005 912 1,701 1,220 1,929 1,149 1,506
Normalized NOPAT Margin
24.48% 2.72% 11.64% 8.94% -67.46% 7.95% 15.51% 10.87% 17.02% 10.08% 13.43%
Pre Tax Income Margin
26.52% 1.42% 14.09% 10.54% -97.06% 14.59% 19.49% 16.56% 24.43% 16.30% 19.69%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
90.29% -54.44% -66.30% -73.22% -77.59% 59.01% 56.96% 58.82% 63.38% 73.03% 68.56%
Augmented Payout Ratio
90.29% -54.44% -66.30% -134.50% -157.54% 123.12% 148.14% 110.92% 107.74% 199.13% 193.13%

Frequently Asked Questions About Bristol-Myers Squibb's Financials

When does Bristol-Myers Squibb's financial year end?

According to the most recent income statement we have on file, Bristol-Myers Squibb's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bristol-Myers Squibb's net income changed over the last 9 years?

Bristol-Myers Squibb's net income appears to be on a downward trend, with a most recent value of -$8.93 billion in 2024, falling from $1.63 billion in 2015. The previous period was $8.04 billion in 2023. Check out Bristol-Myers Squibb's forecast to explore projected trends and price targets.

What is Bristol-Myers Squibb's operating income?
Bristol-Myers Squibb's total operating income in 2024 was -$7.49 billion, based on the following breakdown:
  • Total Gross Profit: $20.96 billion
  • Total Operating Expenses: $28.45 billion
How has Bristol-Myers Squibb revenue changed over the last 9 years?

Over the last 9 years, Bristol-Myers Squibb's total revenue changed from $16.56 billion in 2015 to $48.30 billion in 2024, a change of 191.7%.

How much debt does Bristol-Myers Squibb have?

Bristol-Myers Squibb's total liabilities were at $76.22 billion at the end of 2024, a 16.1% increase from 2023, and a 339.9% increase since 2015.

How much cash does Bristol-Myers Squibb have?

In the past 9 years, Bristol-Myers Squibb's cash and equivalents has ranged from $2.39 billion in 2015 to $14.55 billion in 2020, and is currently $10.35 billion as of their latest financial filing in 2024.

How has Bristol-Myers Squibb's book value per share changed over the last 9 years?

Over the last 9 years, Bristol-Myers Squibb's book value per share changed from 8.55 in 2015 to 8.05 in 2024, a change of -5.8%.



This page (NYSE:BMY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners